iHerb Surpasses $2.4 Billion in Sales, Solidifying Leadership in Global Health and Wellness
Notified -
Globe Newswire24-02-2025, 19:00
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26